Combination chemotherapy with cisplatin and bleomycin in advanced cervical cancer.
Seventeen patients with advanced and recurrent squamous cell cervical cancer were treated with a combination of cisplatin and bleomycin. One complete and nine partial responses were observed (53%). The median duration of response was 8 months and the median survival was 12.7 months (5 months for nonresponders). Response was documented, particularly in patients with nodal disease and lung metastases. No life-threatening toxic effects were reported. This combination appears to be as effective as other combinations, has low toxicity, is well-tolerated, and merits further study.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy
D001761:Bleomycin; D002945:Cisplatin